sponsored
PatientsVille.com Logo

PatientsVille

Leflunomide Medical Research Studies

Up-to-date List of Leflunomide Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Leflunomide Medical Research Studies

Rank Status Study
1 Recruiting Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: Leflunomide
Outcome Measures: thirty percent changes in the ACR Pediatric core set of disease activity measures in at least three of the six response variables (ACR Pedi 30);   50% and 70% changes in the ACR Pediatric core set of disease activity measures in at least three of the six response variables (ACR Pedi 30)
2 Recruiting Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
Conditions: Nephritis;   Lupus
Interventions: Drug: Leflunomide;   Drug: Azathioprine
Outcome Measures: lupus nephritis flare;   24-hour proteinuria over time;   Serum albumin over time;   Number of extra renal flare;   Cumulated glucocorticoid intake
3 Unknown  Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
Condition: Bullous Pemphigoid
Intervention: Drug: Leflunomide
Outcome Measures: Stage 1 : complete clinical remission after 6 months treatment for 9 patients at least among 15 appraisable patients.;   Stage 2 : complete clinical remission after 6 months treatment for 27 patients at least among 43 appraisable patients.;   To determine the rate of clinical complete remission at M9 and M12.;   To estimate the number of patients with immunological remission at M6, M9 and M12.;   To evaluate monthly the tolerance of Leflunomide.
4 Recruiting Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study
Condition: Rheumatoid Arthritis
Interventions: Drug: Methotrexate plus sulfasalazine;   Drug: Leflunomide
Outcome Measures: MRI synovitis score;   MRI bone marrow edema score;   MRI erosion score;   US synovitis score;   clinical outcomes
5 Recruiting The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
Condition: Myasthenia Gravis
Interventions: Drug: Azathioprine;   Drug: Leflunomide
Outcome Measures: the percent of achieving good response;   level of the AChR-Ab
6 Recruiting Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Biological: Rituximab;   Drug: Placebo
Outcome Measures: ACR 50 - Part I of the Study - 50% improvement of ACR defined disease activity;   DAS28 - Part II of the study - evaluation of Disease activity score (DAS)28;   Evaluation of 50 % improvement of ACR defined disease activity (ACR 50);   EULAR response - response to therapy defined by European League against Rheumatism (EULAR);   Assessment of ACR core set consisting of SJC, TJC, HAQ, patient's and physician's global assessments - Visual analog scales (VAS), Subject's pain-scale, CRP, ESR;   Assessment of SF-36 scores (Health survey);   Assessment of FACIT (Functional assessment of chronical illness therapy)-fatigue- Questionnaire;   HAQ (health assessment questionnaire)- assessment;   proportion of DAS28-ESR remission - remission using DAS28 based on the erythrocyte sedimentation rate (ESR) defined as DAS28 < 2.6;   Proportion of patient with disease activity score in 28 joints (DAS28) based on the erythrocyte sedimentation rate (ESR) (DAS28-ESR) - low disease is defined DAS28 < 3.2;   Assessment of changes in c-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) values;   Assessment of changes in rheumatoid factor (RF) and Antibody against cyclic citrullinated peptide (aCCP) values;   Performance of standardized ultrasound synovitis score (US7)in subgroup of patients;   Assessment of changes of rheumatoid nodules (number and diameter of target nodule) during therapy;   Assessment of main safety parameters as SAE, deaths, duration of B-cell depletion and rate of infections + malignancies;   Documentation of used standard care treatment by patients that are non-responder to therapy;   Descriptive analysis of outcome measures in patients differentiated by presence of rheumatoid factor (RF-positive) or absence of rheumatoid factor(RF-negative)
7 Unknown  Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research
Condition: Rheumatoid Arthritis
Interventions: Drug: Leflunomide;   Drug: methotrexate
Outcome Measures: ACR20;   ACR50;   ACR70;   EULAR response:good response;   EULAR response :moderate response
8 Recruiting An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria
Conditions: Viruria;   Viremia
Intervention: Drug: Leflunomide and orotic acid
Outcome Measures: Clearance of viruria;   Absence of viremia;   Absence of Polyoma BK Nephropathy;   No rejection of the renal allograft
9 Recruiting A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome
Condition: Rheumatoid Arthritis
Interventions: Drug: Xinfeng capsule;   Drug: Leflunomide
Outcome Measures: ACR20 (American College of Rheumatology (ACR) criteria of 20% improvement in symptoms );   ACR50 (American College of Rheumatology (ACR) criteria of 50% improvement in symptoms );   ACR70 (American College of Rheumatology (ACR) criteria of 70% improvement in symptoms );   Patterns based on Chinese medicine(CM)symptoms;   Disease Activity Scale (DAS)28;   Rheumatoid arthritis (RA) biomarkers;   Life Quality Assessment;   x-rays of the hands and wrists
10 Recruiting Escape II Myocardium
Condition: Rheumatoid Arthritis
Interventions: Drug: Triple Therapy;   Drug: TNF inhibitors
Outcome Measures: Improvement of left ventricular mass;   Improvement of Left Ventricular Ejection Fraction.;   Improvement in the degree of myocardial inflammation (as indicated by FDG uptake in PET scanning)
11 Recruiting Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis
Conditions: Systemic Sclerosis;   Arthritis
Intervention:
Outcome Measures: Improvement of HAQ-DI (CHAQ-DI in jSSc) by at least -0.21 in one year;   Improvement of the CHFS in one year;   Improvement of the CDAI in one year;   Improvement of the SDAI in one year;   Improvement of the DAS28(We) in one year;   Improvement of the DAS28(CRP) in one year;   Improvement of the 28 (±hand distal interphalangeal) JTC in one year;   Improvement of the 28 (±hand distal interphalangeal) JSC in one year
12 Recruiting To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88);   Other: placebo
Outcome Measures: - The percentage of patients who achieved at least 20% improvement in the American College of Rheumatology (ACR) criteria;   Change in physical function as measured by the average of change from baseline in the health assessment questionnaire-disability index (HAQ-DI) from Wk 8 to Wk 24;   Percentage of patients achieving American College of Rheumatology (ACR) 20/50/70 criteria;   Percentage of patients achieving American College of Rheumatology (ACR) 50/70 criteria;   Changes from baseline in disease activity score (DAS) 28;   Disease activity score (DAS) 28 remission rate;   Change from baseline in short form (SF)-36 domains;   Change from baseline in the Rheumatoid Arthritis-Work Productivity Survey (WPS-RA) items;   Change from baseline in the Functional Assessment of Chronic Illness Therapy Fatigue scale (FACIT-fatigue);   Change from baseline in European Quality of Life-5 dimension (EQ-5D);   Change from baseline in rheumatoid arthritis impact of disease (RAID) scores;   Change from baseline in each individual ACR component
13 Recruiting To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88);   Drug: tocilizumab
Outcome Measure: Safety as measured by adverse events/serious adverse events, physical examinations, clinical laboratory, ECGs.
14 Not yet recruiting Pharmacovigilance in Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents and/or Methotrexate
Condition: Juvenile Idiopathic Arthritis
Intervention:
Outcome Measures: Safety in patients with JIA on biologics/MTX from 3 to 10 years from drug initiation;   Long-term efficacy in patients with JIA on biologics/MTX from 3 to 10 years from drug initiation;   Predictors of safety from 3 to 10 years from drug initiation;   Risk factor from 3 to 10 years from drug initiation;   Number of children in treatment with biologics from 3 to 10 years from drug initiation;   Wrist joint erosion from 3 to 10 years from drug initiation;   Assess the reasons for stopping drug treatment from 3 to 10 years from drug initiation;   Efficacy from 3 to 10 years from drug initiation
15 Recruiting A Study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate and/or Other DMARDS in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra];   Drug: DMARDs
Outcome Measures: Change in Clinical Disease Activity Index (CDAI);   Health Assessment Questionnaire-Disability Index (HAQ-DI);   Short Form Health & Labour Questionnaire (SF-HLQ) ;   Functional Assessment of Chronic Illness Therapy (Fatigue FACIT-F);   Change in Disease Activity Score (DAS28-ESR);   Change in American College of Rheumatology (ACR) scores;   Change in European League Against Rheumatism (EULAR) criteria;   Change in Simplified Disease Activity Index (SDAI);   Remission according to Clinical Disease Activity Index (CDAI) on two consecutive visits;   Change in Tender/Swollen Joint Count (TJC/SJC);   Safety: Incidence of adverse events;   Incidence of anti-therapeutic antibodies;   Global Assessment/Pain visual analogue scale (PGA/Pain-VAS)
16 Recruiting A Study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra];   Drug: DMARD
Outcome Measures: Proportion of patients achieving clinical remission as measured by Disease Activity Score 28 (DAS28) < 2.6 at Week 24;   Proportion of patients who maintain DAS28 remission/low disease activity from Week 24 to Week 52 on RoActemra/Actemra monotherapy;   Proportion of patients who achieve DAS28 remission/low disease activity up to Week 52 for patients with intensification of methotrexate/non-biologic DMARDs in combination with RoActemra/Actemra since Week 24 to Week;   Change in American College of Rheumatology (ACR) scores;   Change in European League Against Rheumatism (EULAR) criteria;   Change in Simplified/Clinical Disease Activity Index (SDAI/CDAI);   Change in Tender/Swollen Joint Count (TJC/SJC);   Proportion of patients with corticosteroid reduction/discontinuation;   Safety: Incidence of adverse events;   Incidence of anti-tocilizumab antibodies;   Soluble interleukin-6 receptor (sIL-6R) levels;   Pharmacokinetics: Plasma concentrations;   Patient reported outcomes: Global Assessment/Pain visual analogue scales (PGA/Pain-VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI)

These studies may lead to new treatments and are adding insight into Leflunomide etiology and treatment.

A major focus of Leflunomide research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Leflunomide